COMIRNATY KP.2 30 micrograms / dose dispersion for injection adults and adolescents from 12 year

Licence status
Authorised: 21/12/2020
Active substances
COVID-19 mRNA vaccine (nucleoside-modified)
Dosage Form
Dispersion for injection
Licence number
EU/1/20/1528/037-038
Licence holder
BioNTech Manufacturing GmbH

Product documents

Licence information

ATC code
J07BN01 covid-19, RNA-based vaccine
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
21/12/2020